FXYD4

Across TCGA pan-cancer cohorts, FXYD4 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of FXYD4’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FXYD4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FXYD4 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC are the cancer types where FXYD4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FXYD4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.827	<.001	12	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

FXYD4–CCRCC

Open the CCRCC breakdown →